|
|||||||||||||||||||||
|
Visit Altogen Biosystems Transfection Resource: RNAi applications (siRNA transfection, microRNA transfection, plasmid DNA transfection), stable and transient DNA transfection, delivery methods, electroporation, microinjection, dendrimer-based, non-viral and virus-mediated gene delivery, liposome and non-liposomal reagents. Transfection of cancer cell lines vs primary cultures. RNA Interference as a research tool for gene expression studies, gene silencing in neuronal cells, RNAi therapeutics and In Vivo Transfection Reagents from Altogen Biosystems.
Hypotriploid human cell line was initiated from an osteosarcoma in a 14 year -old male Caucasian. The modal chromosome number was 66 occurring in 44 percent of cells. The rate of cells with higher ploidies was two percent. Eighteen to 19 marker chromosomes were common to all cells. Osteosarcoma is a highly metastatic cancer, with a redundancy of autocrine loops. Human osteosarcoma cells release matrix degrading enzymes in response to chemokine activation. Many cell lines derived from an osteosarcoma produce high yields of interferon after superinduction with polyinosinic acid polycytidylic acid, cycloheximide, and actinomycin D. SaOS -2 is a non-transformed cell line derived in 1973 from the primary osteosarcoma of an 11-year old Caucasian girl. It was determined in 1987 that SaOS -2 cells possess several osteoblastic features and could be useful as a permanent line of human osteoblast-like cells and as a source of bone-related molecules. SaOS-2 have well-documented characterization data, the possibility to obtain large amounts of cells in short time, and can be fully differentiated in a manner that the osteoblastic cells naturally do. SaOS-2 cells can deposit a mineralization-competent extracellular matrix which makes the cells an important model for investigating events associated with the late osteoblastic differentiation stage in human cells. It has also been shown that Saos-2 cells possess several osteoblastic features and could be useful as a permanent line of human osteoblast-like cells and as a source of bone-related molecules.
siRNA Transfection || Transfection Methods || Stable Transfection || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Transfection || In Vivo Transfection Reagents || Cell Line Specific Transfection Reagents
In Vivo Transfection Reagents || Fibroblast Cells Transfection Reagent || Astrocyte Cells Transfection Reagent || HEK-293 Transfection Reagent || MEF Transfection Reagent || HepG2 Transfection Reagent || CHO Reagent || MDA-MB Transfection Reagent || Cos7 Transfection Reagent || A549 Transfection Reagent || NIH3T3 Reagent || HUVEC Transfection Reagent || LNCaP Transfection Reagent || MCF-7 Reagent || PC-12 Reagent
Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including - generation of stable cell lines, RNA Interference (RNAi) services, assay development, screening and transfection services. Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Altogen Services offers generation of stable cell lines by transforming the cell line of choice to stably express gene of interest or shRNA-encoding construct. Cloning and shRNA expression services are available.
|
||||||||||||||||||||
|
|||||||||||||||||||||
